comparemela.com

Latest Breaking News On - மருத்துவ ஆராய்ச்சி பிரிவு - Page 2 : comparemela.com

Mike Minor and Debra Nichols Join The IMA Group as Executives in Clinical Research

Mike Minor and Debra Nichols Join The IMA Group as Executives in Clinical Research Posted May 19, 2021   Tarrytown, NY – May 19, 2021 –The IMA Group announced today the ongoing expansion of its Clinical Research Division through the addition of two industry veterans with over 65 years of combined clinical, operational, commercial, strategic and scientific experience.  IMA Clinical Research is a physician-founded network of 10 integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. With access to 80 additional, broadly distributed medical offices of The IMA Group, IMA Clinical Research has extensive capabilities to conduct site-based, hybrid and decentralized clinical trials that support the development of safe and effective therapies. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested clinical tri

Mike Minor and Debra Nichols Join The IMA Group as Executives in Clinical Research

Mike Minor and Debra Nichols Join The IMA Group as Executives in Clinical Research
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.

Partnering up with Abiraterone Acetate – Potentials for a Harmonious Relationship

Partnering up with Abiraterone Acetate – Potentials for a Harmonious Relationship Published 03 May 2021 Abiraterone acetate has demonstrated benefit across the metastatic prostate cancer spectrum when combined or layered on conventional androgen deprivation therapy. Whether it be metastatic castration-sensitive (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC) in either the pre-or the post-docetaxel setting, the overall survival benefit is certain. 1-4 Attempts to advance to the next level with additional agents added to abiraterone acetate, in the first-line mCRPC setting, have been met with mixed results. At this time, other than the continuing foundation of androgen deprivation therapy, there is no therapeutic agent regulatory approved for combination with abiraterone acetate.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.